AusperBio Unveils Remarkable AHB-137 Phase IIb Results at EASL
AusperBio Reveals Exciting Clinical Data for AHB-137
Today, AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. together known as AusperBio, proudly announce the presentation of significant interim clinical data at a key global event. During a recent late-breaking poster session at the highly regarded European Association for the Study of the Liver (EASL) Congress, the company showcased advances from their ongoing Phase IIb trial involving AHB-137, a novel treatment targeting chronic hepatitis B virus (HBV) infection.
Innovative Approach with AHB-137
AHB-137 represents a remarkable step forward in biotechnology, functioning as an investigational antisense oligonucleotide (ASO). This innovative therapy aims for a functional cure of chronic hepatitis B, and its current Phase IIb trial examines its efficacy across multiple sites. During the presentation, the team revealed findings on patients who were HBeAg-negative chronic hepatitis B individuals and were receiving nucleos(t)ide analog (NA) therapy.
Impressive Clinical Outcomes
The results presented at EASL were striking. Out of those treated for either 16 or 24 weeks with AHB-137, a significant percentage achieved the primary endpoint of HBsAg and HBV DNA suppression. Specifically, 66% of participants in the 16-week group and 75% in the 24-week group reached HBsAg levels below the established lower limit of quantification.
Moreover, among patients meeting these primary criteria, over 80% experienced a noteworthy decline in HBsAg within just 12 weeks. Further, seroconversion rates at the end of the treatment were recorded at 33% for the 16-week regimen and a remarkable 54% for the 24-week group. Importantly, the treatment was noted to be well-tolerated, showcasing a favorable safety profile across both durations.
Expert Insights on Trial Results
Dr. Guofeng Cheng, the Co-founder and CEO of AusperBio, expressed enthusiasm regarding the results, stating that these interim efficacy and safety data substantiate their earlier Phase IIa results. This growing body of evidence highlights AHB-137's potential as a crucial component in achieving a functional cure for chronic hepatitis B.
Dr. Chris Yang, Co-founder and CSO, echoed this excitement, emphasizing the rapid reduction of HBsAg levels and the impressive seroconversion rates among participants. This reinforces the therapeutic promise AHB-137 holds in the ongoing fight against chronic hepatitis B.
Next Steps in AHB-137's Clinical Journey
As the clinical trial progresses, AusperBio remains grateful to all individuals involved, including principal investigators, clinical staff, and study participants. Their hard work and dedication are pivotal in advancing AHB-137 towards its potential fruition.
AHB-137 is currently undergoing trials as part of a broader strategy to revolutionize treatments for chronic hepatitis B. With compelling Phase 1 and Phase IIa data revealed in previous conferences, this innovative approach is gaining significant attention and support.
About AusperBio
AusperBio stands at the forefront of clinical-stage biopharmaceutical innovation, committed to developing transformative therapies for chronic hepatitis B and similar conditions. Leveraging their proprietary Med-Oligo™ ASO technology, AusperBio aims to revolutionize oligonucleotide therapeutics by enhancing how therapies are delivered and how efficiently they operate.
With headquarters in both the USA and China, AusperBio engages in extensive research and development, actively striving towards breakthroughs that address pressing healthcare challenges. Their focus remains on promoting therapeutic innovations that pave the way toward improved patient outcomes and health advancements.
Frequently Asked Questions
What is AHB-137?
AHB-137 is a novel investigational antisense oligonucleotide designed to target chronic hepatitis B virus infection, aiming for a functional cure.
What were the key findings from the Phase IIb trial?
The trial demonstrated that 66% and 75% of participants achieved significant viral suppression in 16-week and 24-week treatment groups, respectively.
Who are the key figures involved in this study?
Notable contributors include Dr. Guofeng Cheng and Dr. Chris Yang, who highlighted the promising efficacy and safety of AHB-137 during presentations.
How is AHB-137 administered in the clinical trials?
Patients receive AHB-137 through a structured treatment plan over either 16 or 24 weeks, as part of the Phase IIb trial.
What are AusperBio's future plans for AHB-137?
AusperBio aims to continue advancing AHB-137 through clinical trials, with the goal of establishing its effectiveness in curing chronic hepatitis B.
About The Author
Contact Lucas Young privately here. Or send an email with ATTN: Lucas Young as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
